THERASOURCE, LLC
Roslyn, NY · Biotech · Private
Recombinant human MFG-E8 (rhMFG-E8) protein therapeutic for acute radiation syndrome
therasourcellc.com →- Grants
- $16M
- 24 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20142016201820202022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · A Novel Recombinant Protein for Mitigating Total Body Radiation Injury | $294,693 | |
| Federal grant | Department of Health and Human Services · Phase I · Preclinical Testing of Human Ghrelin for the Treatment of Stroke | $5,000 | |
| Federal grant | Department of Health and Human Services · Phase I · rhMFG-E8 as an Effective Adjuvant Therapy for Hemorrhagic Shock | $224,951 | |
| Federal grant | Department of Health and Human Services · Phase II · Human Ghrelin as an Effective Mitigator of Acute Radiation Injury | $2,956,148 | |
| Federal grant | Department of Health and Human Services · Phase I · A Novel Recombinant Protein as an Effective Therapy for Acute Kidney Injury | $335,318 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical Testing of Human Ghrelin and Growth Hormone for Sepsis in the Elderly | $540,425 | |
| Federal grant | Department of Health and Human Services · Phase I · rhMFG-E8 as an Effective Adjuvant Therapy for Hemorrhagic Shock | $112,474 | |
| Federal grant | Department of Health and Human Services · Phase II · Human Ghrelin as an Effective Mitigator of Acute Radiation Injury | $991,403 | |
| Federal grant | Department of Health and Human Services · Phase I · Preclinical Development of a Novel Small Molecule Drug for Sepsis | $222,172 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical Testing of Human Ghrelin and Growth Hormone for Sepsis in the Elderly | $540,425 | |
| Federal grant | Department of Health and Human Services · Phase I · A Novel Recombinant Protein as an Effective Therapy for Acute Kidney Injury | $112,808 | |
| Federal grant | Department of Health and Human Services · Phase I · Preclinical Development of a Novel Small Molecule Drug for Sepsis | $111,168 | |
| Federal grant | Department of Health and Human Services · Phase II · Human Ghrelin as an Effective Mitigator of Acute Radiation Injury | $982,276 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical Testing of Human Ghrelin and Growth Hormone for Sepsis in the Elderly | $486,925 | |
| Federal grant | Department of Health and Human Services · Phase I · A New Therapy for Acute Kidney Injury | $299,999 | |
| Federal grant | Department of Health and Human Services · Phase II · rhMFG-E8 as an Effective Adjuvant Therapy for Hemorrhagic Shock | $505,554 | |
| Federal grant | Department of Health and Human Services · Phase II · A Novel Recombinant Protein for Mitigating Acute Radiation Injury | $2,923,149 | |
| Federal grant | Department of Health and Human Services · Phase I · A New Therapy for Acute Kidney Injury | $139,504 | |
| Federal grant | Department of Health and Human Services · Phase II · rhMFG-E8 as an Effective Adjuvant Therapy for Hemorrhagic Shock | $505,554 | |
| Federal grant | Department of Health and Human Services · Phase II · A Novel Recombinant Protein for Mitigating Acute Radiation Injury | $974,383 | |
| Federal grant | Department of Health and Human Services · Phase II · rhMFG-E8 as an Effective Adjuvant Therapy for Hemorrhagic Shock | $986,433 | |
| Federal grant | Department of Health and Human Services · Phase II · A Novel Recombinant Protein for Mitigating Acute Radiation Injury | $974,383 | |
| Federal grant | Department of Health and Human Services · Phase I · eCIRP-Neutralizing mAb for Acute Lung Injury in Sepsis | $259,510 | |
| Federal grant | Department of Health and Human Services · Phase I · eCIRP-Neutralizing mAb for Acute Lung Injury in Sepsis | $129,820 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1150 | PAFOSPHARMA, LLC | — | — |
| 1151 | Adaptive Phage Therapeutics, Inc. | — | $45M |
| 1152 | SERION, INC. | — | — |
| 1153 | THERASOURCE, LLC | — | — |
| 1154 | LOHOCLA RESEARCH CORPORATION | — | — |
| 1155 | ENSIGN PHARMACEUTICAL, INC. | — | — |
| 1156 | ALLIANCE DISCOVERY, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.